A number of N-substituted pyrimidine acyclic nucleosides were synthesized by coupling reaction of 2-(2-chloroethoxy)ethyl acetate or (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate with the corresponding base followed by deprotection. The synthesized compounds were tested for their antiviral activity against hepatitis B virus (HBV). The plaque reduction infectivity assay was used to determine virus count reduction as a result of treatment with the synthesized compounds which showed moderate to high antiviral activities.
Introduction
Pyrimidines are an important class of compounds which have widespread applications from pharmaceuticals to materials (Brown, 1996) . They have been recognized as important heterocyclic compounds due to their diverse biological activities, such as Tie-2 kinase inhibitory (Malibu and Kappe, 2007) , HIV-1 inhibitory (Gadhachanda et al., 2007) , antimalarial (Agarwal et al., 2005) , secretive adenosine A1 receptor antagonistic (Chang et al., 2004) , anticancer (Capdeville et al., 2002) , analgesic (Zaki et al., 2006) , cardiovascular (Atwal, 1987) , and antiallergic (Ozeki et al., 1989) activities. Furthermore, it has been found that 3,4-dihydropyrimidin-2(1H)-ones (DHPMs) have an interesting multifaceted pharmacological profi le as hepatitis B virus (HBV) replication inhibitors (Kappe, 2000; Deres et al., 2003; Lengar and Kappe, 2004) . A number of synthetic pharmacophores with antibacterial (Hegab et al., 2007) , antifungal (Atul et al., 2008) , and antimycotic activities (Keutzberger and Gillessen, 1985) are based on the pyrimidyl moiety. Also, pyrimidines are present in numerous natural products and, signifi cantly, in the pyrimidine and purine bases ribo-and deoxyribonucleosides (Lister, 1971; Hoffmann, 1996; Hurst, 1980; Brown, 1984) . On the other hand, nucleoside analogues are structurally, metabolically, and pharmacodynamically related agents that have diverse biological actions and therapeutic effects including antiviral (Remy and Secrist, 1985; Abdel-Aal et al., 2006; Rashad et al., 2008) and antitumour (Chu et al., 1984; Park et al., 1986; Lin and Liu, 1985) activities. Furthermore, the acyclic nucleoside (Mereyala and Gurijala, 1993; El Ashry et al., 2005 , 2006 El Kilany, 1996, 1997) analogues including modifi cations of both the acyclic glycon and aglycon parts are biological inhibitors and have stimulated extensive research as (El Ashry et al., 2000 . The importance of the substituted hydroxyalkyl chain conformation in the interaction of acyclic nucleosides with enzymes has been demonstrated (Alvarez et al., 1994) . Moreover, the 5-substituted derivatives of pyrimidine acyclonucleoside analogues have exhibited pronounced inhibitory properties with respect to uridine phosphorylase and have enhanced antitumour action (Park et al., 1986; Lin and Liu, 1985) . Owing to the above signifi cance and our interest in the synthesis of new and potent antiviral nucleoside analogues (El-Sayed et al., 2008; El-Zayate et al., 2009; Ali et al., 2007) , herein we report the synthesis and anti-HBV activity of new substituted pyrimidine acyclic nucleosides.
Results and Discussion

Chemistry
The coupling reaction at N-1 of the substituted pyrimidine derivatives with acyclic and cyclic oxygenated halides is the most effi cient route to our target acyclic nucleosides. Thus, the reaction of the substituted pyrimidin-2,4-dione derivatives 1a-c with 2-(2-chloroethoxy)ethyl acetate (2) in N,N-dimethylformamide (DMF) and in the presence of sodium hydride at room temperature (r.t.) afforded the corresponding substituted 2-{2-[2,4-dioxo-3-phenyl-3,4-dihydropyrimidin-(2H)-1-yl]ethoxy}ethyl acetate derivatives 3a-c in for the CN group of compound 3a. The 1 H NMR spectra of 3a-c showed four CH 2 groups, each as a triplet at δ 3.82 -4.92 ppm, the methyl group at δ 2.38 -2.44 ppm in addition to the signals of aromatic protons at δ 6.78 -7.92 ppm. When the (2,4-dioxo-3,4-dihydropyrimidin-(2H)-1-yl)ethoxyethyl) acetate derivatives 3a-c were treated with methanolic ammonia solution at room temperature, the corresponding substituted 1-[2-(hydroxymethoxy)ethyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivatives 4a-c were produced in 70 -72% yields. The structures of the deprotected acyclic nucleoside analogues 4a-c were established on the basis of their IR, 1 H NMR, and elemental analyses data which all agreed with the assigned structures. The IR spectra showed an absorption band at 3420 -3440 cm -1 for the OH group and revealed the absence of the carbonyl ester group. Furthermore, the 1 H NMR spectra revealed the disappearance of the peak corresponding to the methyl group, and instead a signal corresponding to the OH group appeared at δ 4.35 ppm.
The reaction of the substituted pyrimidin-2,4-dione derivatives 1a-c with (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate (5) in DMF and in the presence of sodium hydride at room temperature afforded the corresponding substituted ethyl 1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidines 6a-c in 80 -82% yields. The 
Antiviral activity
The synthesized compounds were tested for their antiviral activity against HBV using the HepG2.2 -2.15 cell line, a human hepatoplastoma cell line producing hepatitis B viral particles (Korba and Gerin, 1992) . The results of our preliminary screening indicated that compounds 4a-c and 7a showed the highest effect at 10 μg/10 5 cells, while compounds 7b and 7c showed moderate activity (Tables I and II) .
In conclusion, new acyclic nucleosides were synthesized in order to increase the number of compounds screened for antiviral activity. Some of them displayed promising activities.
Experimental
General
Melting points were determined using a Büchi apparatus. IR spectra (KBr) were recorded with a Bruker-Vector22 instrument (Bruker, Bremen, (J values) are given in Hz. The progress of the reactions was monitored by TLC using aluminum silica gel plates 60 F 245 . EI-mass spectra were recorded with a HP D5988 A 1000 MHz instrument (Hewlett Packard, Palo Alto, CA, USA). Antiviral activity against HBV was tested at the Liver Institute, Menoufi a University, Shebin El-Koam, Egypt.
Antiviral activity
The synthesized compounds were tested for their antiviral activity against hepatitis B virus (HBV) using the HepG2.2 -2.15 cell line (Sells et al., 1987) , a human hepatoplastoma cell line producing HBV particles (Korba and Gerin, 1992) .
The cell line was maintained in RPMI-1640 (Glutamax) (Gibco BRL Life Technologies, Paisly, Scotland) culture medium containing 100 IU/mL nystatin (Gibco BRL Life Technologies), 380 μg/mL G418 (genetecin) (Gibco BRL Life Technologies), and 10% fetal calf serum (FCS) (Gibco BRL Life Technologies). The transferred HepG2.2 -2.15 cells were kept in a tissue culture fl ask at 37 ºC and 5% CO 2 . Subcultures were set up after one week by trypsination [10% versin/ trypsin (Biochrome KG, Berlin, Germany)] and transferred to a 96-well tissue culture plate. Serial dilutions of the test compounds were added to the cell suspension and incubated for 6 d at 37 ºC and 5% CO 2 . The antiviral activity and cytotoxic effect of the test compounds was estimated by comparing the DNA content in the culture supernatant and the viability of the cells containing the test compounds with those of HepG2.2 -2.15 cells containing no compounds added to their supernatant (blank cells). The drug lamivudine (4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one, GlaxoSmithKline, Uxbridge, UK) which is a potent selective inhibitor of HBV replication has been used as a standard positive control. Each compound was tested in triplicate.
DNA extraction
DNA extraction was done by incubating 10 μL of diluted supernatant with 10 μL of 0.2 M NaOH at 37 ºC for 1 h, then carefully adding 9.6 μL of 0.2 M HCl, followed by addition of 90 μL of Tris-EDTA [2-amino-2-(hydroxymethyl)-1,3-propanediol-EDTA (TE) (Gibco BRL Life Technologies)] buffer.
PCR-ELISA detection of HBV DNA
The DNA content in the cell culture supernatant was determined by PCR amplifi cation of the HBV DNA using 1 μmol/L of each of the following primers: HCID-1 (5′-GGAAAG AAGTCAGAAGGCA-3′) and HCID-2 (5′-TT-GGGGGAGGAGATTAGGTT-3′), in a reaction mixture containing 14 μL extracted supernatant, 4 mmol/L MgCl 2 , 10 μmol/L DIG-11-dUTP (Roche, Munich, Germany), 190 μmol/L dTTP, 200 μmol/L dATP, dGTP, dCTP (Roche), 1.5 U Taq polymerase (Roche), in a total volume of 50 μL. PCR reaction conditions were: 32 cycles of 10 min at 94 ºC, 30 s at 58 ºC, and 30 s at 72 ºC, with a 3-s increment for each cycle, in a Perkin Elmer 480 thermal cycler (Perkin Elmer, Waltham, MA, USA). The PCR product was detected by the DIG-ELISA assay (Roche). The optical density (OD) of DNA of the test compounds was compared to that of the blank culture.
Cytotoxicity assay
3-(3,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, St. Louis, MO, USA) is a colourless substrate that is transferred to a coloured product by any living cell but not by dead cells. The assay utilizes MTT to test the viability of the cells in the presence of the test compound compared to the viability of the blank cells (Fouad et al., 1998) .
Calculation of IC 50 , CC 50 and SI values
The 50% inhibitory concentration (IC 50 ) of an antiviral drug was determined by plotting the DNA content of the serial dilutions of the tested compound versus the concentration of this compound. The 50% cytotoxic effect (CC 50 ) was calculated from the average viability of the cells in proportion to the concentration of the drug. The selective index (SI) was calculated as CC 50 /IC 50 .
